In rheumatoid arthritis (RA), a complex cytokine network drives chronic infl ammation and joint destruction. So far, few attempts have been made to identify the cellular sources of individual cytokines systematically. Therefore, the primary objective of this study was systematically to assess the cytokine messenger RNA expression profi les in the fi ve largest cell populations in the synovial fl uid and peripheral blood of RA patients. To refl ect the in vivo situation as closely as possible, the cells were neither cultured nor stimulated ex vivo. Methods Infl ammatory cells from 12 RA patients were sorted into CD4 and CD8 T cells, B cells, macrophages and neutrophils. mRNA expression for 41 cytokines was determined by real-time PCR using microfl uidic cards. Receptor activator nuclear factor kappa B ligand (RANKL) (TNFSF11) expression by B cells was further confi rmed by fl ow cytometry and by immunofl uorescence staining of frozen sections of synovial tissue from patients with RA.
receptor activator nuclear factor kappa B ligand (RANKL) and lymphotoxin beta (LT-β). 12 -15 B cells have proved to be a successful therapeutic target in RA, highlighting an important role for this cell type beyond their ability to produce antibody. RA synovial B cells can produce several cytokines including LT-β, which may be required for synovial ectopic lymphoid tissue formation and IL-6, which implicates a direct pro-infl ammatory role. 16 17 On the other hand, an IL-10-producing B-cell subset has been attributed with anti-infl ammatory properties. 18 19 So far, this population has not been described in the RA synovium. Macrophages are regarded as an important source of pro-infl ammatory cytokines found in the RA synovium including TNFα, IL-1 and IL-18. 13 20 21 Through expression of IL-7, IFNβ, IL-23, B-cell-activating factor of the TNF family (BAFF) and (a proliferation-inducing ligand) APRIL, synovial macrophages are thought to play a role in synovial T-cell and B-cell differentiation and survival. 22 -26 Neutrophils represent the largest cell population in rheumatoid synovial fl uid and produce a range of cytokines including IL-1β, BAFF, APRIL and transforming growth factor beta (TGFβ) as well as the chemokines CCL3 and CXCL8. 25 27 -30 To date, no study has systematically determined cytokine production by synovial fl uid cell populations. The aim of the present study was therefore to identify the predominant cellular sources of cytokines in RA by comparing their expression across fi ve populations in RA synovial fl uid and peripheral blood. To achieve this we developed a new approach, which has the advantage of characterising cytokine profi les in cells directly ex vivo without culture or previous stimulation to refl ect the in vivo situation as closely as possible. Importantly, this strategy has enabled us to identify B cells infi ltrating the synovial fl uid and synovial tissue of RA patients as a major source of RANKL. This cytokine plays an important role in driving bone destruction in RA, and results from trials using a fully human monoclonal antibody specifi c for RANKL (denosumab) confi rm its role in erosive progression. 31 
METHODS Patients
Synovial fl uid and peripheral blood were obtained from 12 patients fulfi lling the 1987 American College of Rheumatology criteria for RA. 32 All patients had disease of more than 3 months' duration. Synovial fl uid was aspirated from joints under palpation or ultrasound guidance. Synovial tissue was taken by ultrasound-guided biopsy and ▶ Supplementary fi gures are published online only. To view these fi les please visit the journal online ( http://ard.bmj. com ).
immediately frozen in liquid nitrogen. All patient material was obtained in agreement with the Helsinki declaration. Local ethical approval was obtained and participants gave informed, written consent. Further clinical details are shown in table 1 .
Isolation of cell populations
Synovial fl uid was incubated with 1000 U/ml endotoxin-free hyaluronidase (Hyalase; Wockhardt, UK) at 37°C for 15 min to reduce viscosity. Mononuclear cells were isolated using density gradient centrifugation and stored at −80°C. Mononuclear cells were stained with mouse anti-human CD14-FITC (Immunotools, Friesoythe, Germany), CD19-PE (Immunotools), CD3-PE (eBioscience), CD45RO-FITC (Biostat, Stockport, UK), CD4-APC (eBioscience) and CD8-PE Cy7 (eBioscience) on ice. Cells were sorted into CD14, CD19, CD3 CD45RO CD4 and CD3 CD45RO CD8 populations using a MoFlo cell sorter (Beckman Coulter, High Wycombe, UK). Neutrophils were isolated from synovial fl uid and peripheral blood by anti-CD15 microbeads (Miltenyi Biotec, Bisley, UK) and a magnetic-activated cell sorter. Isolated populations used had a minimum purity of 95%. 
TaqMan low-density array analysis

Immunofl uorescence staining of synovial tissue
Immunofl uorescence staining was performed on 5 μm tissue sections using mouse anti-CD3 (UCHT-1, University of Birmingham), mouse anti-CD19 FITC (Dako) and rabbit anti-RANKL (AbCam, Cambridge, UK). CD3 was developed with goat anti-mouse Cy5 (Southern Biotech, Alabama, USA), CD19 was developed with goat anti-mouse FITC (Southern Biotech) and goat Alexa Fluor 488 anti-FITC (Molecular Probes, Paisley, UK), and RANKL was developed with donkey anti-rabbit Rhodamine (Jackson ImmunoResearch, Newmarket, UK). Concentration, and in the case of monoclonal antibodies, isotype-matched antibodies were used as controls. Sections were incubated at room temperature with primary antibody for 1 h, washed in phosphate buffered saline (PBS), and incubated with secondary/tertiary antibodies for 30 min. PBS with 2% bovine serum albumin was used as a diluent. For nuclear counterstaining, sections were immersed in Hoechst 33258 (Sigma, Gillingham, UK) at 20 μg/ ml for 2 min. A Zeiss confocal LSM 510 microscope (Zeiss, Welwyn Garden City, UK) was used to capture images for processing using LSM Image Examiner software (Zeiss).
Flow cytometry
Mononuclear cells from synovial fl uid and peripheral blood were stained with mouse anti-RANKL-PE (eBioscience) and CD19-Pacifi c Blue (Biolegend, Cambridge, UK) or CD19-AlexaFluor 700 (eBioscience). PBS with 0.5% bovine serum albumin was used as a diluent and washing buffer. Flow cytometry was performed using a Cyan ADP High Performance fl ow cytometer (Beckman Coulter). Data were analysed using SUMMIT and FlowJo.
RESULTS
We developed a novel technical approach to systematically determine messenger RNA expression of 41 cytokines in T cells, B cells, macrophages and neutrophils isolated from a single sample of synovial fl uid or peripheral blood from RA patients (see supplementary fi gure 1, available online only). In each of the isolated cell populations, the cytokine mRNA expression profi le was determined by real-time PCR. In a series of validation experiments we excluded bias due to sample preparation, normalisation and staining techniques ( fi gure 1 ). The results of these preliminary experiments confi rmed the robustness of the experimental approach taken and thus the validity of the results obtained in this study.
The complete set of data showing a range of cytokine expression patterns in all fi ve cell populations in peripheral blood and synovial fl uid of RA patients is shown in the supplementary data (supplementary fi gure 1A-D, available online only). IL-4, IL-5, Anti-CCP, anti-cyclic citrullinated peptide; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate.
IL-13, IL-22, CCL11, CXCL12, CSF-3 and EGF mRNA was undetectable in the majority of patients (data not shown). Positive controls (mRNA from T cells stimulated with magnetic beads coated with anti-CD3 and anti-CD28 antibody and a commercially available blend of RNA from human cell lines representing different tissues (Stratagene, Stockport, UK)) were used to test whether these assays worked. With the exception of CSF-3 all of the cytokine mRNA species were detected.
A selection of cytokines expressed predominantly by lymphocytes in the synovial fl uid is shown in fi gure 1 . In synovial fl uid T cells we detected the expression of IFNγ and IL-2 mRNA. In the CD4 cell population we observed the expression of IL-17A mRNA suggesting the presence of T-helper (Th) type 17 cells. We also found that IL-21, a cytokine reportedly produced by Th17 cells, was expressed in the CD4 T-cell population. 33 The cytokines IL-12 and IL-23 are important regulators of differentiation and survival of Th1 and Th17 cells, respectively. Both cytokines are produced as heterodimers and have a common p40 subunit. The synovial fl uid B-cell population expressed high levels of IL-12p40 as well as IL-12p35 mRNA, suggesting that these cells may produce functionally active IL-12 ( fi gure 2 ). In agreement with previous publications, T cells expressed mRNA coding for the IL-23p19 subunit, which combines with the IL-12p40 subunit. 34 However, T cells did not express IL-12p40 mRNA, again leaving B cells as the only cell population among those analysed here expressing mRNA for both subunits required for the production of IL-23. High levels of mRNA-expression for CSF-2 (granulocyte macrophage colony-stimulating factor) by CD4 T cells suggests a role for these cells in neutrophil survival. LT-β and IL-7 mRNA were both expressed in T cells and B cells, indicating a contribution of both cell types to B-cell development and T-cell survival.
Intriguingly, RANKL (TNFSF11) mRNA was expressed predominantly by synovial fl uid B cells. Previous studies have reported the expression of RANKL by RA synovial fi broblasts, T cells and chondrocytes, but this is the fi rst report of RANKL expression in B cells in RA. We also found RANKL gene expression in CD4 T cells, but at a lower level compared with B cells. The expression of RANKL at the protein level is described in a later section of this paper and in fi gure 5 .
The data shown in fi gure 3 describe cytokine mRNA expression found predominantly in the synovial fl uid myeloid cell populations investigated (neutrophils and macrophages). Our results indicate that macrophages constitute the major source of the pro-infl ammatory cytokine IL-1β, the Th1-differentiation factor IL-18 and IL-27, which is implicated in the differentiation of several T-cell subsets. Macrophages were also found to be the main source of APRIL, CCL2, CCL3 and VEGF-α mRNA expression in RA synovial fl uid, confi rming their role in directing immune cell migration and differentiation as well as angiogenesis. Synovial fl uid neutrophils were found to express a range of cytokines very similar to macrophages. Particularly prominent was their expression of IFNα1, CXCL8 and BAFF mRNA. Cytokines highly expressed in both lymphocyte and myeloid cell populations are shown in fi gure 4 . IL-1α was expressed at similar levels by macrophages, B cells and neutrophils in RA synovial fl uid. B cells and macrophages comprised the major sources of IL-6, while T cells and macrophages were the primary producers of IL-10 mRNA. T-cell, B-cell and macrophage populations all expressed IL-15. TNFα, TGFβ1, MIF and CCL4 mRNA were highly expressed by all lymphocyte and myeloid cell populations investigated.
Comparison of cytokine profi les in all fi ve cell populations in synovial fl uid and peripheral blood showed that a wide range of cytokines was expressed at a higher level in synovial fl uid (see supplementary fi gure 3, available online only). In the T-cell, B-cell and macrophage populations the majority of cytokines detected were over-expressed at the site of infl ammation, in the synovial fl uid. Interestingly, this was not the case for neutrophils.
Several novel observations of cytokine gene expression have been made in the context of this study. Because of its clinical relevance to the progression of joint destruction in RA patients, the observation of RANKL mRNA expression in synovial fl uid B cells was extended to the protein level. First, the mRNA gene expression data were normalised to cell number ( fi gure 5A ) in order to exclude potential bias arising from normalisation to 18S rRNA. Confi rming our original observation, PCR data normalised to cell number identifi ed synovial fl uid CD19 B cells as the dominant producers of RANKL mRNA, while a smaller proportion of CD4 T cells also showed RANKL mRNA expression. The surface expression of RANKL on synovial fl uid mononuclear cells was determined by co-labelling for CD19 and RANKL and fl ow cytometric analysis. While only a very small proportion of B cells expressed RANKL in the peripheral blood of RA patients, a signifi cantly higher proportion of B cells from synovial fl uid samples expressed RANKL on their surface ( fi gure 5 ).
A large proportion of the B cells in the infl amed joint are localised in the synovial tissue, while they are a relatively small population among the synovial fl uid cells (see supplementary fi gure 2, available online only). To test whether synovial tissue B cells produced RANKL, frozen sections of synovial tissue from biopsies taken from RA patients with active disease were stained with antibodies to RANKL and CD19. Distinct RANKL expression was identifi ed in CD19+ B cells in the infl amed synovium ( fi gure 5 ). This observation was mainly made in B cells dispersed throughout the sublining and more rarely in lymphoid aggregates.
DISCUSSION
In this study a novel strategy was used to compare cytokine expression in the fi ve dominant immune cell populations in the synovial fl uid and peripheral blood of RA patients without ex vivo stimulation. We also detected the expression of several chemokines and growth factors that contribute to cell recruitment and survival in the RA joint. 35 While many cytokines were found in the populations we would have predicted based on the existing literature, we also made several unexpected fi ndings. Notably, we observed that synovial fl uid B cells express high levels of pro-infl ammatory cytokines. The B-cell population was the only synovial fl uid population that expressed both IL-12p35 and IL-12p40, the two subunits that are required for the production of functional IL-12. This observation is supported by previous reports of IL-12 production by B cells. 36 Synovial fl uid B cells also expressed IL-23p19, the subunit that heterodimerises with IL-12p40 to form IL-23, indicating that synovial fl uid B cells also have the capacity to produce functional IL-23. We found that IL-23p19 was expressed predominantly by synovial fl uid T cells, in agreement with the original publication that reported high levels of IL-23p19 in polarised Th1 cells. 34 However, our observation that synovial fl uid CD4 and CD8 T cells do not express IL-12p40 mRNA raises the question of whether synovial fl uid T cells express a yet undescribed alternative binding partner for IL-23p19. A discrepancy between the level of IL-23p19 mRNA expression and functional expression of IL-23 at the protein level has also been described in RA synovial tissue and fi broblast-like synoviocytes. 37 While it is thought that differentiation towards plasma cells and the production of rheumatoid factor and anti-citrullinated protein antibodies contribute to disease, B cells are likely to play further roles. Antigen presentation by B cells is likely to play a role in the local activation of T cells thus indirectly increasing T-cell cytokine production, but little is known about direct cytokine production by B cells in the RA synovium. 38 An antiinfl ammatory role has been proposed for a subset of B cells that can produce IL-10. 18 peripheral blood of patients with autoimmune diseases including RA, but have not been reported in the rheumatoid joint so far. The mRNA cytokine profi le of synovial fl uid B cells detected in this study does not support a major contribution of B cells to IL-10 production, but rather supports a generally proinfl ammatory role for this cell type in the synovial fl uid. This is the fi rst study to report that B cells contribute to RANKL production in the infl amed rheumatoid joint. Previous studies have reported the expression of RANKL by RA synovial fi broblasts, T cells and chondrocytes, and that levels of soluble RANKL are elevated in synovial fl uid compared with the serum of RA patients. 41 -44 RANKL is known to be required for osteoclast development and plays a key role in mediating bone erosion. 45 Of relevance to our observation that synovial B cells express this cytokine, RANKL has been identifi ed as part of a distinct expression profi le that defi nes a subset of memory B cells that normally reside in epithelial niches. 46 Furthermore, RANKL has been detected in B cells in the gingival tissue of patients with periodontal disease and in plasma cells in osteolytic myeloma bone disease, in which it is associated with bone degradation. 47 48 RANKL-defi cient mice have altered B and T cell populations and lack lymph nodes indicating that RANKL plays a role in lymphocyte development and lymph node organogenesis. 45 The development of ectopic lymphoid structures and lymphoid neogenesis is a poorly understood feature of many chronic infl ammatory diseases including RA. 49 It will be intriguing to investigate how the production of RANKL by B cells at sites of chronic infl ammation contributes to the development of these lymphoid aggregates.
Data from the REFLEX trial revealed that the B-cell targeting therapy rituximab, in combination with methotrexate, caused signifi cant reduction in joint damage progression compared with methotrexate alone. 50 Together with our observation of RANKL production by B cells in the synovial tissue and fl uid of RA patients, this suggests that depletion of RANKL-expressing B cells may contribute to the inhibition of bone erosion by rituximab. 50 
